Clinical Trial: A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants

U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07204418) titled 'A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants' on Sept. 24.

Brief Summary: The purpose of this study is to evaluate the pharmacokinetics (PK) of xanomeline following administration of KarXT in CYP2D6 normal/extensive, intermediate, poor, and ultrarapid metabolizers.

Study Start Date: Oct. 14

Study Type: INTERVENTIONAL

Condition: Healthy Volunteers

Intervention: DRUG: Xanomeline/ Trospium Chloride

Specified dose on specified days

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Karuna Therapeutics

Published by HT Digital ...